AlzeCure Pharma AB (publ) (ALZCUR.ST)

SEK 1.17

(0.0%)

Market Cap (In SEK)

103.3 Million

Revenue (In SEK)

-

Net Income (In SEK)

-37.16 Million

Avg. Volume

46.04 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.94-4.0
PE
-
EPS
-
Beta Value
0.286
ISIN
SE0010133785
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Martin Jönsson
Employee Count
-
Website
https://www.alzecurepharma.se
Ipo Date
2018-11-28
Details
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.